Transdermal Gender Affirming Hormone Therapy at Lower Doses Achieves Affirmed-Gender Hormone Targets with Minimal Biochemical Impact
Gender-affirming hormone therapy (GAHT) forms the cornerstone of the medical management of transgender and gender-diverse (TGD) individuals, improving psychological well-being and facilitating desired physical changes. Transdermal GAHT, favoured for its reduced adverse effects, remains under-researched in its efficacy and risk profiles at lower doses. This study aimed to evaluate longitudinal effects of transdermal GAHT, focussing on affirmed-gender sex steroid levels and associated biochemical parameters.
